An audit of thiopurine methyltransferase genotyping and phenotyping before intended azathioprine treatment for dermatological conditions

Clinical and Experimental Dermatology

Volumn 35, Issue 2, 2010, Pages 140-144

  Vestergaard, T ^a   Bygum, A ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENT; METHYLTRANSFERASE;

ABDOMINAL PAIN; ADULT; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; ATOPIC DERMATITIS; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CONTACT DERMATITIS; DERMATOMYOSITIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG WITHDRAWAL; DYSPEPSIA; ECZEMA; ENZYME ASSAY; FATIGUE; FEMALE; GENOTYPE; HAIR LOSS; HEADACHE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LEUKOPENIA; LICHEN PLANUS; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MUCOUS MEMBRANE PEMPHIGOID; NAUSEA; NEURODERMATITIS; NUMMULAR DERMATITIS; OUTCOME ASSESSMENT; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PHENOTYPE; POMPHOLYX; PRIORITY JOURNAL; PRURIGO; PSORIASIS; PYODERMA GANGRENOSUM; RASH; REMISSION; RETROSPECTIVE STUDY; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; URTICARIA; VASCULITIS; VOMITING; WELLS SYNDROME; WILD TYPE; ADOLESCENT; AGED; CHILD; GENETICS; MIDDLE AGED; SKIN DISEASES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AZATHIOPRINE; CHILD; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLTRANSFERASES; MIDDLE AGED; PHENOTYPE; RETROSPECTIVE STUDIES; SKIN DISEASES; YOUNG ADULT;

EID: 75849163831     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2009.03446.x     Document Type: Article

References (15)

1. Anstey AV, Wakelin S, Reynolds NJ. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004 151: 1123 1132.
2. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980 32: 651 662.
3. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989 46: 149 154.
4. Evans WE, Hon YY, Bomgaars L et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercatopurine or azathioprine. J Clin Oncol 2001 19: 2293 2301.
5. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 2006 55: 369 389.
6. Fargher EA, Tricker K, Newman W et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 2007 32: 187 195.
7. Jackson AP, Hall AG, McLelland J. Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine. Br J Dermatol 1997 136: 133 134.
8. Tavadia SM, Mydlarski PR, Reis MD et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000 42: 628 632.
9. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002 29: 2507 2512.
10. Krynetski EY, Tai HL, Yates CR et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996 6: 279 290.
11. McLeod HL, Lin JS, Scott EP et al. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994 55: 15 20.
12. Otterness D, Szumlanski C, Lennard L et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997 62: 60 73.
13. Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol 2002 147: 308 315.
14. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006 367: 839 846.
15. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995 131: 193 197.